Grifols Sa S/Adr (GIKLY)

Grifols SA Was incorporated on June 22, 1987. It is a specialty biopharmaceutical company that develops, manufactures and distributes a broad range of plasma derivative products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. The Company operates in four business divisions: Bioscience, Diagnostic, Hospital and Raw Materials and Others. The Bioscience division includes activities relating to the manufacture of plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation and purification of plasma, and the sale and distribution of end products. The main plasma products it manufactures are IVIG, Factor VIII, A1PI and albumin. It also manufactures intramuscular immunoglobulins, ATIII, Factor IX and plasma thromboplastin component, or PTC. The Diagnostic division focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, including analytical instruments and reagents for diagnostics, as well as blood bank products. The Company concentrates its Diagnostic business in immunohematology and hemostasis product lines. The Diagnostic division's main customers are blood donation centers, clinical analysis laboratories and hospital immunohematology services. The Raw Material division provides raw materials for its intravenous therapy products like plastic and glass bottles, which the company purchases from various European suppliers. The Hospital division manufactures and installs products used by and in hospitals, such as parenteral solutions and enteral and parenteral nutritional fluids, which are sold almost exclusively in Spain and Portugal. It also includes products that the company do not manufacture. The Company operates in Latin America, in countries such as Mexico, Colombia, Argentina, Chile and Brazil. It sells Bioscience, Diagnostic and Hospital products to hospitals and clinics, GPOs, governments and other distributors globally. The Company's operations are subject to government authorities in the United States, at the federal, state and local level, and in other countries in which it operates.